Innovation Pharmaceuticals Inc (IPIX)

[Chronic]

ffrol, the press release said nothing about duration. In fact, duration didn't improve vs. placebo. If you look at the trial design, duration is defined as time from initial WHO Grade 3 to the final Grade 3 assessment before SOM never returns.

While Brilacidin-OM appeared to decrease the initial duration of SOM (time from the initial WHO Grade ≥ 3 to the first WHO Grade ≤ 2 OM assessment), detailed interpretation of this and other duration data comparisons were limited.

So Brilacidin did decrease initial duration, but the company is clearly implying that the SOM returned in many patients so overall duration showed no statistical improvement over placebo.